Abstract:OBJECTIVE:To construct a recombinant adenovirus vector expressing TbetaR-II extracellular domain-RANTES fusion gene and evaluate its anti-tumor effects.METHODS:Mouse origin TbetaR-II extracellular domain and RANTES gene were amplified by RT-PCR. The TbetaR-II extracellular domain-RANTES fusion gene was amplified by overlapping PCR method. TbetaR-II extracellular domain-RANTES fusion gene was cloned into pDC316 vector. The recombinant adenovirus vector expressing the fusion gene was constructed by adMax adenovirus vector creation system. Recombinant adenovirus vector expressing the fusion gene was transfected into LA795 cells. The expression of recombinant adenovirus was checked by Westen blot. The levels of TGF-beta1, RANTES in supernatant were checked by ELISA. The transfected cells were counted and growth curve was obtained. Apoptosis of transfected cells was detected by Annexin V FITC method. The chemotactic activity of supernatant of transfected cells to splenic lymphocytes was assayed. Transfected cells (1 x 10(5)) were inoculated into T739 mice and to observe the tumor growth and survival time. Ad-TbetaR-II extracellular domain, Ad-RANTES and Ad-TbetaR-II extracellular domain-RANTES fusion gene(1 x 10(10) pfu) were injected into the tumor in T739 mice. The tumor size and tumor weight were recorded and tumor growth inhibition rate was counted and statistically analyzed.RESULTS:TbetaR-II extracellular domain and RANTES gene were amplified by RT-PCR and TbetaR-II extracellular domain-RANTES fusion gene amplified by overlapping PCR, were identified by DNA sequence analysis. Restriction enzyme digestion analysis showed that the recombinant vector was constructed correctly. The recombinant adenovirus vector expressing the fusion gene was constructed successfully using the AdMax Adenovirus Vector Creation System. Its titer was 8 x 10(10) pfu/ml. Ad-TbetaR-II extracellular domain-RANTES fusion gene was transfected into LA795 cells and had specific protein fragment proved by Western Blot. The concentration of TGF-beta1 was decreased and RANTES was increased in supernatant of transfected cells. The growth curve showed that recombinant adenovirus vector expressing the fusion gene could delay tumor development and induce apoptosis, with an apoptosis rate in vitro of 16.9%. The supernant of infected cells showed chemotactic activity to splenic lymphocytes. Tumor growth and survival time were prolonged significantly in group tranfected with recombinant adenovirus vector expressing the fusion gene, and tumor growth was effectively inhibited after injecting recombinant adenovirus vector expressing the fusion gene, with a tumor growth inhibition rate of 37.6%.CONCLUSION:A recombinant adenovirus vector expressing TbetaR-II extracellular domain-RANTES fusion gene has been constructed successfully. The recombinant adenovirus vector can bind TGF-beta1 effectively, counteract immune suppression mediated by TGF-beta, enhance immune function, induce significant antitumor immune respone, inhibit tumor growth, and prolong the survival time of tumor-bearing mice.

[Serial Recombinant Expression and Anti-Tumor Activity in Vitro of Antibiotic Peptide Alloferon-1].

[Serial Recombinant Expression and Activity Against Tumor Cells in Vitro of Antibacterial Peptide Alloferon-1].

Expression of recombinant BC047440 protein and its effects on proliferation of HepG2 cells in vitro

AN ANTI-TUMOR RESEARCH OF RECOMBINANT PHAGE VACCINE EXPRESSED XENOGENIC EGFR

Inhibition of Tumor Growth by Recombinant Adenovirus Containing Human Lactoferrin Through Inducing Tumor Cell Apoptosis in Mice Bearing Emt6 Breast Cancer

The Construction of Anti-EGFR Single Chain Variable Fragment Fused with Gelonin Toxin Prokaryotic Expressing Plasmid and the Study of Its Anti-tumor Effects

Construction of Prokaryotic Expression System of Staphylococcal Enterotoxin B Gene and Effects of Its Expressed Product on Promoting Lymphocyte Proliferation and Inhibiting the Growth of Tumor Cell

Study of alloferon, a novel immunomodulatory antimicrobial peptide (AMP), and its analogues

Preparation of the Antiangiogenic Peptide Alphastatin Recombinant Adeno-Associated Virus

[Construction of Eukaryotic Expression Vector of Mouse Alpha-Fetoprotein Cdna and Its Expression in Dendritic Cells and in Vitro Antitumor Effect on Hepatoma].

A Novel Tumor-Activated ALA Fusion Protein for Specific Inhibition on the Growth and Invasion of Breast Cancer Cells MDA-MB-231

Synthesis of α-gal epitopes on human digestive tract tumor cell

Genetic Recombinant Expression and Characterization of Human Augmenter of Liver Regeneration

[Construction of Recombinant Adenovirus Vector Expressing Extracellular Domain of TbetaR-II-RANTES Fusion Gene and Its Anti-Tumor Effects].

Novel Production Method of Innovative Antiangiogenic and Antitumor Small Peptides in Escherichia Coli

An EGF Receptor-Targeting Amphinase Recombinant Protein Mediates Anti-Tumor Activity in Vitro and in Vivo

Prokaryotic Expression, Purification of HSP65-MUC1 VNTR2 Fusion Protein and Primary Research on Its Tumoricidal Effect

[Allokin-alpha - new approaches in the treatment of chronic virus Epstein-Barr infections]

An Efficient Scheme for Purification of a Novel Recombinant Immunotoxin, Rcck8pe38, for Anti-Tumour Experiments.

Characterization of Recombinant Toxin rCCK96-104PE38 Targeting Colon Cancer

The study of antitumor activity in vitro and in vivo of TRAIL-Fc